

Appendix S3. Univariable regression analysis

Univariable regression analysis between Beliefs about Medicines Questionnaire (BMQ)-Specific (Necessity and Concerns) and patient general characteristics in patients treated with methotrexate (MTX) and Biologics

Variables	Necessity				Concerns			
	MTX beta [CI]	p-value	Biologics beta [CI]	p-value	MTX beta [CI]	p-value	Biologics beta [CI]	p-value
Age	0.05 [-0.018; 0.117]	0.15	0.003 [-0.064; 0.070]	0.92	-0.003 [-0.063; 0.057]	0.91	0.016 [-0.037; 0.069]	0.55
Sex	-1.313 [-3.157; 0.531]	0.16	-0.597 [-2.486; 1.292]	0.53	-0.060 [-1.698; 1.577]	0.94	-1.268 [-2.735; 0.198]	0.09
Age at onset of psoriasis, years	0.052 [-0.011; 0.114]	0.10	-0.013 [-0.085; 0.059]	0.72	-0.019 [-0.074; 0.037]	0.51	0.014 [-0.042; 0.070]	0.62
PASI at the time of the survey	-0.269 [-0.465; -0.073]	0.01	-0.343 [-0.598; -0.087]	0.01	0.005 [-0.173; 0.184]	0.95	0.034 [-0.174; 0.242]	0.75
Diagnosis of PsA	-0.194 [-2.859; 2.470]	0.89	0.987 [-1.071; 3.045]	0.34	1.444 [-0.881; 3.768]	0.22	-1.195 [-2.803; 0.412]	0.14
Disease duration at the time of the survey, years	-0.011 [-0.078; 0.057]	0.76	0.016 [-0.053; 0.085]	0.65	0.018 [-0.041; 0.077]	0.55	0.004 [-0.051; 0.058]	0.89
Age at start treatment, years, mean ± SD	0.008 [-0.066; 0.082]	0.83	-0.002 [-0.069; 0.065]	0.95	0.005 [-0.061; 0.070]	0.89	0.017 [-0.036; 0.069]	0.53
Treatment duration, years	0.197 [0.06; 0.34]	0.007	0.161 [-0.167; 0.489]	0.33	-0.015 [-0.144; 0.114]	0.81	-0.016 [-0.276; 0.243]	0.9
History of conventional therapies	-0.512 [-1.500; 0.477]	0.31	-0.248 [-1.229; 0.734]	0.62	-0.774 [-1.634; 0.085]	0.08	-0.502 [-1.267; 0.264]	0.19
History of biologic therapies	-0.390 [-2.247; 1.467]	0.68	-0.559 [-1.376; -0.259]	0.18	-0.927 [-2.551; 0.696]	0.26	0.088 [-0.560; 0.737]	0.79

PASI: Psoriasis Area and Severity Index, PsA: Psoriatic Arthritis; SD: standard deviation; CI: confidence interval. Significant *p*-values (*p* < 0.2) are shown in bold.

Univariable regression analysis between the Necessity-Concerns differential (NCD) and patient general characteristics in patients treated with methotrexate (MTX) and biologics

Variables	NCD			
	MTX beta [CI]	p-value	Biologics beta [CI]	p-value
Age	0.053 [-0.033; 0.139]	0.22	-0.013 [-0.097; 0.072]	0.77
Sex	-1.253 [-3.597; 1.090]	0.29	-0.671 [-3.045; 1.703]	0.58
Age at onset of psoriasis (years)	0.070 [-0.008; 0.149]	0.08	-0.027 [-0.117; 0.063]	0.55
PASI at the time of the survey	-0.274 [-0.525; -0.023]	0.03	-0.377 [-0.700; -0.053]	0.02
Diagnosis of PsA (yes/no)	-1.638 [-4.993; 1.718]	0.34	2.182 [-0.378; 4.742]	0.09
Disease duration at the time of the survey (years)	-0.029 [-0.114; 0.057]	0.51	0.012 [-0.075; 0.099]	0.79
Age at start treatment (years), mean ± SD	0.003 [-0.091; 0.097]	0.95	-0.019 [-0.103; 0.066]	0.66
Treatment duration (years)	0.212 [0.031; 0.393]	0.02	0.177 [-0.235; 0.590]	0.39
History of conventional therapies	0.263 [-0.993; 1.519]	0.68	0.254 [-0.979; 1.487]	0.68
History of biologic therapies	0.537 [-1.812; 2.887]	0.65	-0.647 [-1.675; 0.381]	0.22

PASI: Psoriasis Area and Severity Index; PsA: psoriatic arthritis. Significant *p*-values (*p* < 0.2) are shown in bold.